Prediction of BCNU Pulmonary Toxicity in Patients with Malignant Gliomas: an Assessment of Risk Factors

Overview

Journal N Engl J Med

Specialty General Medicine

Date 1980 Jul 24

PMID 7383088

Citations 24

Authors

P A Aronin

M S MAHALEY Jr

S A Rudnick

L Dudka

J F Donohue

R G Selker

P Moore

Affiliations

Soon will be listed here.

Abstract

Symptomatic pulmonary disease occurred in 20 per cent of 93 patients with anaplastic gliomas being treated with carmustine (BCNU). An analysis of the variables has revealed a relation between the occurrence of pulmonary toxicity on the one hand, and the total cumulative dose of BCNU, the number of cycles over which the BCNU was administered, the history of lung disease, the patient's age, and the platelet-count nadir after the first course of BCNU on the other. An equation has been generated that allows prediction of pulmonary toxicity during the course of therapy with BCNU with 80 per cent accuracy. Pretreatment analysis of individual cases should allow safe use of BCNU and prevention of most of the serious pulmonary complications caused by this drug.

Citing Articles

Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study.

Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y BMC Pulm Med. 2024; 24(1):495.

PMID: 39379903 PMC: 11462669. DOI: 10.1186/s12890-024-03284-3.

The impact of pulmonary function in patients undergoing autologous stem cell transplantation.

Duque-Afonso J, Ewald S, Ihorst G, Waterhouse M, Struessmann T, Zeiser R Blood Adv. 2021; 5(21):4327-4337.

PMID: 34610094 PMC: 8579263. DOI: 10.1182/bloodadvances.2021004863.

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.

Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wasch R, Bertz H Bone Marrow Transplant. 2020; 56(1):110-120.

PMID: 32591641 PMC: 7319212. DOI: 10.1038/s41409-020-0986-2.

Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.

Azzalin A, Nato G, Parmigiani E, Garello F, Buffo A, Magrassi L Neoplasia. 2017; 19(4):364-373.

PMID: 28319810 PMC: 5358953. DOI: 10.1016/j.neo.2017.02.009.

Impairments that influence physical function among survivors of childhood cancer.

Wilson C, Gawade P, Ness K Children (Basel). 2015; 2(1):1-36.

PMID: 25692094 PMC: 4327873. DOI: 10.3390/children2010001.